NEW YORK, NY / ACCESSWIRE / April 12, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
OTRK Shareholders Click Here: https://www.zlk.com/pslra-1/ontrak-inc-loss-submission-form?prid=14571&wire=1
ATNX Shareholders Click Here: https://www.zlk.com/pslra-1/athenex-inc-loss-submission-form?prid=14571&wire=1
ROOT Shareholders Click Here: https://www.zlk.com/pslra-1/root-inc-information-request-form?prid=14571&wire=1
* ADDITIONAL INFORMATION BELOW *
Ontrak, Inc. (NASDAQ:OTRK)
OTRK Lawsuit on behalf of: investors who purchased November 5, 2020 - February 26, 2021
Lead Plaintiff Deadline : May 3, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ontrak-inc-loss-submission-form?prid=14571&wire=1
According to the filed complaint, during the class period, Ontrak, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Ontrak's largest customer evaluated the Company on a provider basis, valuing Ontrak's performance based on achieving the lowest cost per medical visit rather than clinical outcomes or medical cost savings; (2) as a result, Ontrak's largest customer did not find the Company's program to be effective and was reasonably likely to terminate its contract with Ontrak; (3) because this customer accounted for a significant portion of the Company's revenue, the loss of the customer would have an outsized impact on Ontrak's financial results; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Athenex, Inc. (NASDAQ:ATNX)
ATNX Lawsuit on behalf of: investors who purchased August 7, 2019 - February 26, 2021
Lead Plaintiff Deadline : May 3, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/athenex-inc-loss-submission-form?prid=14571&wire=1
According to the filed complaint, during the class period, Athenex, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the data included in the Oral Paclitaxel plus Encequidar NDA presented a safety risk to patients in terms of an increase in neutropenia-related sequalae; (ii) the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by BICR; (iii) the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR; (iv) the Company's Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommended a new such clinical trial; (v) as a result, it was foreseeable that the FDA would not approve the Company's NDA in its current form; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
Root, Inc (NASDAQ:ROOT)
This lawsuit is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Root Class A common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering conducted on or about October 28, 2020.
Lead Plaintiff Deadline : May 18, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/root-inc-information-request-form?prid=14571&wire=1
According to the filed complaint, (i) Root would foreseeably fail to generate positive cash flow for at least several years following the IPO; (ii) accordingly, the Company would foreseeably require significant cash infusions to meet its cash flow needs; (iii) notwithstanding the Defendants' touting of Root's purportedly unique, data-driven advantages, several of the Company's established industry peers in fact possessed significant competitive advantages over Root with respect to, inter alia, telematics data and data engagement; and (iv) as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP